0224 GMT - Medical-imaging tech-provider Pro Medicus needs to improve the visibility of its business pipeline or demonstrate an ability to speed up market-share gains in order to turn Macquarie analysts more positive on the stock. The analysts moderate their market-share assumption to 10% in fiscal 2027, from 11% previously. They say to clients in a note that they have largely factored in the announcement of further contract wins and renewals. Pro Medicus has yet to demonstrate material uptake of opportunities in adjacent specialities, such as cardiology, they say, adding that they see the stock as fairly valued following a recent de-rate. Macquarie trims its target price by 0.4% to A$257.40, maintaining a neutral rating. Shares are down 7.6% at A$210.405. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
March 26, 2025 22:24 ET (02:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。